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Abstract
Background: The elderly population has increased in many countries. Indications for cancer treatment in elderly
patients have expanded, because surgical techniques and medical management have improved remarkably.
Pancreaticoduodenectomy (PD) requires high-quality techniques and perioperative management methods. If it is
possible for elderly patients to withstand an aggressive surgery, age should not be considered a contraindication
for PD. Appropriate preoperative evaluation of elderly patients will lead to their safer management. The purpose of
the present study was to evaluate the safety of PD in patients older than 75 years and to show the influence of
advanced age on the morbidity and mortality associated with this operation.
Patients and methods: Subjects were 98 patients who underwent PD during the time period from April 2005 to
April 2011. During this study, 31 patients were 75 years of age or older (group A), and the other 67 patients were
less than 75 years old (group B). Preoperative demographic and clinical data, surgical procedure, pathologic
diagnosis, postoperative course and complication details were collected prospectively and they were analyzed in
two group.
Results: There was no statistical difference between patient groups in terms of gender, comorbidity, preoperative
drainage, diagnosis, or laboratory data. Preoperative albumin values were lower in group A (P = 0.04). The mean
surgical time in group A was 408.1 ± 73.47 min. Blood loss and blood transfusion were not significantly different
between both groups. There was no statistical differences in mortality rate (P = 0.14), morbidity rate (P = 0.43), and
mean length of hospital stay (P = 0.22) between both groups.
Long-term survival was also no statistically significant difference between the two groups using the log-rank test
(P = 0.10).
Conclusion: It cannot be ignored that the elderly population is getting larger. We must investigate the
management of elderly patients after PD and prepare further for more experiences of PD. If appropriate surgical
management is provided to elderly patients, we suggest that PD will lead to no adverse effects after surgery, and
PD can be performed safely in elderly patients. We conclude that age should not be a contraindication to PD.
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Background
The elderly population has increased in many countries.
Indications for cancer treatment in elderly patients have
expanded, because surgical techniques and medical man-
agement have improved remarkably. However, given that
the morbidity and mortality associated with surgical
procedures are poorly defined in this population, the
decision to perform an operation in an elderly patient
can be difficult [1]. Therefore, surgeons must give this
decision careful consideration. Pancreaticoduodenectomy
(PD), which may cause considerable complications,
including pancreatic fistula, intra-abdominal bleeding,
intra-abdominal abscess, sepsis and organ failure,
requires high-quality techniques and perioperative man-
agement methods. Though PD is performed in many
hospitals, its associated morbidity and mortality rates are
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40% of patients, despite refinements in surgical techni-
ques and perioperative management methods [2-5]. In
spite of its high rate of morbidity, this aggressive surgery
is considered curative. It has been suggested that patients
who undergo PD appear to benefit from referral to a
high-volume center [6-8]. If it is possible for elderly
patients to withstand an aggressive surgery, age should
not be considered a contraindication for PD [9]. Appro-
priate preoperative evaluation of elderly patients will lead
to their safer management. In fact, it has been reported
that PD can be performed safely in elderly patients
[10-12].
The purpose of the present study was to evaluate the
safety of PD in patients older than 75 years and to show
the influence of advanced age on the morbidity and
mortality associated with this operation.
Methods
Protocol
Subjects were 98 consecutive patients who underwent PD
during the time period from April 2005 to April 2011. The
final diagnoses of these patients were Pancreatic carci-
noma (n = 39), Cholangiocarcinoma (n = 37), Ampullary
carcinoma (n = 8), Intraductal papillary mucinous neo-
plasm (n = 6), Duodenal carcinoma (n = 3), Gastric carci-
noma (n = 1), Duodenal invasion by colon carcinoma (n =
1) and Others (n = 3). The operative technique chosen for
pancreatic anastomosis involved drainage of the pancreatic
s t u m pi n t oa ni s o l a t e dl o o po ft h ej e j u n u mw i t ha ne n d -
to-side, duct-to-mucosa anastomosis, including a pancrea-
tic stent in all cases. Two techniques were applied in a
strictly alternating way. As a result, the patients were allo-
cated to two groups: (a) an internal stent group that
underwent PD involving a pancreatic stump anastomosis
to an isolated loop of the jejunum with an end-to-side,
duct-to-mucosa anastomosis with an internal stent and (b)
an external stent group that underwent PD with an exter-
nal stent.
Surgical technique
Conventional or pylorus-preserving PD (PPPD) was per-
formed at the discretion of the individual surgeon.
Lymph nodes around the head of the pancreas, the
common hepatic artery, and the hepatoduodenal liga-
ment were dissected. Wedge or segmental resection of
the portal vein or superior mesenteric vein was per-
formed when the pancreatic head mass was inseparable
from the vein. After resection, anastomoses were con-
structed to a single jejunal loop, which was repositioned
up into the supra-mesocolic compartment in a retrocolic
manner.
Pancreaticojejunal anastomosis was performed in an
end-to-side fashion. The patients were allocated to the
internal stent group and the external stent group. After
pancreaticojejunal anastomosis, an end-to-side, single
layer, interrupted hepaticojejunostomy without stenting
was performed. The operation was completed with an
end-to-side duodenojejunostomy with mechanical dila-
tion of the pylorus 40 cm downstream from the
pancreaticojejunostomy.
Perioperative management
Twenty-six patients underwent PD, and seventeen
patients underwent substomach-preserving PD (SSPPD)
with Child reconstruction. Fifty-five patients underwent
PPPD with Traverso reconstruction. Pancreatic anasto-
mosis after PD, SSPPD and PPPD was performed by
duct-to-mucosal, end-to-side pancreaticojejunostomy in
all enrolled patients.
Perioperative management was standardized. All
patients received broad-spectrum antibiotics for two days
and an H2 blocker (famotidine) during the entire post-
operative hospital course. No prophylactic somatostatin
or Octreotide was used. The nasogastric tube was
removed on the first postoperative day when discharge
was less than 500 ml. The volume of fluid drained from
the peripancreatic drains and from the pancreatic duct
was measured daily. Patients were kept nil per os for
the first five postoperative days, after which the diet was
gradually resumed if there was no evidence of delayed
gastric emptying, pancreatic leakage or other intra-
abdominal complications. Total parenteral nutrition was
used only in patients who could not tolerate a diet after
postoperative day five. The peripancreatic drains were
removed if there was no evidence of leakage. If there was
evidence of leakage or suspicion of infective complica-
tions (fever, leukocytosis or purulent drain fluid), the
peripancreatic drains were left in-situ, and a contrast
computed tomography (CT) scan was performed to look
for any intra-abdominal collection.
Patients were discharged with the pancreatic duct
catheter in-situ, and this was removed at our outpatient
clinic after the fourth postoperative week.
Data collection
Preoperative demographic and clinical data, surgical
procedure, pathologic diagnosis, postoperative course
and complication details were collected prospectively.
Statistical analysis
Continuous data are expressed as mean ± standard
deviation (SD). The c2 test was used to compare quali-
tative parameters, and Student’s t-test was used for
quantitative parameters. Patient overall survival was
evaluated using the Kaplan-Meier method and com-
pared with the log-rank test. P < .05 was considered
significant.
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Patient characteristics
PDs were performed in 98 patients at our institution
between April 2005 and April 2011. During this study, 31
patients (31.6%) were 75 years of age or older (group A),
and the other 67 patients (68.4%) were less than 75 years
old (group B). There was no statistical difference between
patient groups in terms of gender, comorbidity, preopera-
t i v ed r a i n a g e ,d i a g n o s i s ,o rl aboratory data (hemoglobin,
total bilirubin, amylase, hemoglobin A1c). Preoperative
albumin values were lower in group A than in group B
(P = .04). Patient characteristics and preoperative labora-
tory datas according to age group are shown in Table 1.
Of 90 total patients over 75 years that we saw, we
decided not to perform surgery for 59 (65.6%). PD was
decided for all of the elderly patients for whom surgery
could be performed. In our institution, the indication for
PD is resectable cases, as well as younger patients. PD
was performed in the absence of peritoneal or distant
metastases and when a tumor was not locally advanced.
Cases with limited invasion of a portal or superior
mesenteric vein were considered to be resectable.
Operative outcomes
The 31 PDs (standard PD in 6 patients (19.4%), SSPPD in
7 (22.6%) and PPPD in 18 (58.1%)) performed in group A
included Cholangiocarcinoma in 15 (48.4%) patients,
Pancreatic adenocarcinoma in 8 (25.8%), Ampullary car-
cinoma in 5 (16.1%), Intraductal papillary mucinous neo-
plasm in 2 (6.5%), and Gastric carcinoma in 1 (3.2%). The
67 PDs (standard PD in 20 patients (29.9%), SSPPD in 10
(14.9%) and PPPD in 37 (55.2%)) performed in group B
Table 1 Patient characteristics and laboratory data
group A group B P value
n = 31 n = 67
patient characteristics
Age (years) 79.09 ± 3.49 61.69 ± 6.37 < .0001
Gender 0.14
male 16 45
female 15 22
Body mass index 23.04 ± 3.85 22.82 ± 3.84 0.8
Comorbidity
Hypertension 13 20 0.24
Hyperlipoproteinemia 5 7 0.42
Diabetes mellitus 5 12 0.83
Cardiac disease 2 5 0.86
Plumonary disease 1 1 0.57
Chronic renal disease 1 0 0.14
cerebral disease 0 3 0.23
Other 1 0 0.14
Preoperative biliary drainage
Yes 24 48 0.55
No 7 19
Diagnosis
Pancreatic adenocarcinoma 8 31 0.08
Cholangiocarcinoma 15 22
Ampullary carcinoma 5 3
Intraductal papillary mucinous neoplasm 2 4
Duodenal carcinoma 0 3
Gastric carcinoma 1 0
Duodenal invasion of colon carcinoma 0 1
Other 0 3
Laboratory data
Hemoglobin 12.20 ± 1.81 14.24 ± 15.42 0.46
Total bilirubin 6.90 ± 7.10 4.85 ± 5.01 0.16
Amylase 91.48 ± 44.93 153.48 ± 234.91 0.15
Hemoglobin A1c 5.70 ± 2.08 6.29 ± 2.03 0.32
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patients, Cholangiocarcinoma in 22 (32.8%), Intraductal
papillary mucinous neoplasm in 4 (6.0%), Ampullary car-
cinoma in 3 (4.5%), Duodenal carcinoma in 3 (4.5%),
Duodenal invasion of colon carcinoma in 1 (1.5%), and
Other in 3 (4.5%).
The mean surgical time in group A was 408.1 ± 73.47
min, which was significantly shorter than that in group
B (P = .04). Blood loss and blood transfusion were not
significantly different between groups (Table 2).
Pathologic results
The American Joint Committee on Cancer (AJCC) cancer
staging distribution was 4 (13.3%) stage 0, 9 (30%) stage I,
16 (54.3%) stage II, and 1 (3.3%) stage III in group A and
2 (3.2%) stage 0, 25 (39.1%) stage I, 34 (53.7%) stage II,
and 3 (6.7%) stage III in group B. The mean tumor size
was 27.17 ± 12.18 mm in group A and 30.59 ± 13.64 mm
in group B (P = .25). The distribution of histological
grades in group A was as follows: 12 (38.7%) well differen-
tiated, 9 (29%) moderately differentiated, 4 (12.9%) poorly
differentiated, 3 (9.7%) papillary, and 3 (9.7%) other. In
group B, it was as follows: 14 (21%) well differentiated, 27
(40.6%) moderately differentiated, 13 (20%) poorly differ-
entiated, 7 (10.7%) papillary, and 6 (9.1%) other (Table 3).
Postoperative outcome
The mean postoperative stay in group A was 25 ± 16.46
days, which was longer than that in group B (21.54 ±
10.32 days), but the difference was not significant. One
in-hospital death occurred in group A on postoperative
day 22. There was no significant difference in mortality
rate between group A and group B (3.2% vs. 0%, P =
.14). The overall complication rate was 50.0% (54.8% in
group A and 46.3% in group B; P = .43). The most com-
mon complication was pancreatic fistula (32.7%). The
incidence of pancreatic fistula was similar in group A
and group B (38.7% vs. 29.9%, respectively; P = .38).
There was also no significant difference in the occur-
rence of other complications: delayed gastric emptying,
liver abscess, wound infection, intraabdominal bleeding,
respiratory insufficiency, intraabdominal collection, sep-
sis, bile leakage, or gastrointestinal bleeding. There are
summarized in Table 4.
Long-term survival
The mean follow up was 15.8 months in group A (median:
12.0 months; range, 0.8-65.4 months) and 23.3 months in
group B (median: 18.8 months; range, 1.3-59.5 months).
The 1- and 3-year survival rates were 70.0% and 50.5%,
respectively, in group A and 84.8% and 65.9%, respectively,
in group B. There was no statistically significant difference
between the two groups using the log-rank test (P = .10).
Discussion
There have been many cases of PD since the first report
by Wipple et al. in 1935 [13]. However, the incidence of
postoperative complications is still 30%-60%[14-16]. PD
may cause considerable complications, including pan-
creatic fistula, intra-abdominal bleeding, intra-abdominal
Table 2 Operative outcomes
group A group B P value
n = 31 n = 67
Type of pancreaticoduodenectomy
PPPD 18 37 0.44
SSPPD 7 10
PD 6 20
Pancreatic texture
soft 26 47 0.04
hard 5 27
Tumor size (mm) 27.17 ± 12.18 30.59 ± 13.64 0.25
Pancreatic duct diameter (mm) 3.61 ± 3.03 4.03 ± 2.94 0.58
Pancreatic drainage
internal 12 28 0.77
external 19 39
Surgical time (min) 408.1 ± 73.47 461.76 ± 84.98 0.003
Blood loss (ml) 948.58 ± 468 1225.5 ± 925.82 0.12
Blood transfusion (ml) 209.33 ± 425.62 231.64 ± 510.57 0.84
Portal vein resection
Yes 1 8 0.16
No 30 59
PD = pancreaticoduodenectomy; SSPPD = substomach preserving pancreaticoduodenectomy; PPPD = pylorus preserving pancreaticoduodenectomy.
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quality techniques and management methods in the
perioperative period. Though PD is performed in many
hospitals, its associated morbidity and mortality rates
are high. However, the rate of morbidity and mortality
associated with PD has decreased, especially in high-
volume centers [6-8]. Complications tend to be lower in
institutions that perform more than a certain number of
surgeries and have more than a certain number of staff
medical specialists; such institutions provide better man-
agement of complications, which provides the strength
of the recommendation. It was suggested that PD was
contraindicated in most elderly patients, because such
aggressive surgery would result in perioperative compli-
c a t i o n s .Y e oe ta l[ 1 7 ]n o t e dt h a ta g ea p p e a r st ob ea n
important predictor of death in low-volume centers but
not in high-volume centers. Several studies reported
that age was not an independent risk factor for perio-
perative mortality and morbidity following PD [11,18].
S i n c eP Di st h eo n l yc h a n c et h e s ep a t i e n t sh a v ef o ra
cure, we suggest that PD is justified, even in the elderly.
If appropriate management of elderly patients is pro-
vided, the safety of perioperative management will be
secured in high-volume centers. Therefore, it has been
reported that patients should not be excluded from PD
due to age [10].
In our institution, we also investigated the safety of
elderly patients following PD. Patients aged 75 years and
Table 3 Pathological results
group A group B P value
n=3 1 n=6 7
AJCC T stage 0.28
is 4 2
13 1 1
21 0 1 6
31 2 3 2
41 3
AJCC Nodal status 0.87
N0 16 33
N1 14 31
AJCC Stage 0.34
04 2
IA 1 9
IB 8 16
IIA 3 6
IIB 12 27
III 1 2
Grade of neoplasm 0.43
well 12 14
moderately 9 27
poorly 4 13
papillary 3 7
other 3 6
AJCC = The American Joint Committee on Cancer
Table 4 Postoperative outcomes
group A group B P value
n=3 1 n=6 7
Complications
Pancreatic fistula 12 20 0.38
Grade A 5 5
Grade B 6 15
Grade C 1 0
Delayed gastric emptying 2 4 0.93
Liver abscess 0 1 0.49
Bowel obstruction 0 0 1
Wound infection 5 5 0.19
Intraabdominal bleeding 1 2 0.95
Respitory insufficiency 4 3 0.13
Intraabdominal collection 3 3 0.32
Sepsis 1 0 0.14
Bile leakage 1 0 0.14
Gastrointestinal bleeding 0 1 0.49
Postoperative outcomes
Postoperative hospital stay (day) 25 ± 16.46 21.54 ± 10.32 0.22
Mortality 1 0 0.14
Morbidity 17 31 0.43
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pared to younger patients (group B), with no differences
in patient characteristics and preoperative laboratory
data, excluding albumin. Moreover, there was no differ-
ence in morbidity and mortality between groups. The
mean surgical time for group A was significantly shorter
than that for group B (P < 0.01). It was suggested that
this was because a portal vein resection was done for
o n l y1o f3 1p a t i e n t s( 3 . 2 % )i ng r o u pA ,w h i c hw a sl e s s
than that done in group B (11.9%), although this differ-
ence was not significant. Pancreatic fistula is the most
threatening complication of PD. In the literature, the
rates of pancreatic fistula range from 5% to 40%[2-5]. In
the present study, the incidence of pancreatic fistula was
s i m i l a rb e t w e e no l d e ra n dy o u n g e rp a t i e n t s( 4 5 . 1 %v s .
29.9%, respectively; P = .14), though there was a tendency
for increased normal pancreatic texture (soft pancreas) in
older patients (P = .04). Several reports compared exter-
nal drainage and no-stent procedures and found that the
incidence of fistula was significantly lower for external
drainage [3,19]. The normal pancreas preserves exocrine
function, and its main pancreatic duct is narrow. Thus,
one cannot rule out the possibility of injury during surgi-
cal manipulation. The diameter of the pancreatic duct is
approximately 1-2 mm in the normal pancreas, and post-
operative swelling can develop temporarily that can result
in stenosis. Thus, stent placement is considered essential
at our institution. It is thought that placement of an
external drain can minimize the leakage from a branch of
remnant pancreatic duct. The external drain reduces the
stress at the anastomotic site by a pressure gradient and
minimizes the outflow into the branch of the pancreatic
duct. We placed an external drain for the normal pan-
creas. We suggest that an external drain reduces the inci-
dence of pancreatic fistula in a normal pancreas.
Older patients also had similar lengths of postoperative
hospital stay compared with younger patients. The rate
of overall survival in older patients tended to be lower
compared with younger patients, though the difference
was not statistically significant. Recently, most patients
with pancreatic carcinoma receive adjuvant chemother-
apy [20]. It is difficult to compare older and younger
patients, as we did not manage some older patients after
surgery, because we considered the side effects of che-
motherapy due to their age, especially for those over 80
years of age. Aloia et al report delayed recovery after PD
[21]. Because patient age was independently associated
with a decreased likelihood of receiving adjuvant therapy
by multivariate analysis, we suggest that it might be bet-
ter to avoid adjuvant chemotherapy after surgery for
elderly patients. Except for this matter, our data showed
no significant differences in postoperative morbidity and
mortality between older and younger PD patients.
The results of several series [22-26] suggest that age is
unrelated to morbidity and mortality and that PD can
be performed safely if it is provided by appropriate indi-
cation and management. Our study also addresses the
safety of PD management in elderly patients and sup-
ports these opinions.
Conclusion
In conclusion, it cannot be ignored that the elderly
population is getting larger. We must investigate the
management of elderly patients after PD and prepare
further for more experiences of PD. If appropriate surgi-
cal management is provided to elderly patients, we sug-
gest that PD will lead to no adverse effects after surgery,
and PD can be performed safely in elderly patients. We
conclude that age should not be a contraindication
to PD.
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